Shanghai Heartcare Medical Technology Corp. Ltd. Class H (HK:6609)
:6609
Want to see HK:6609 full AI Analyst Report?
6609 Stock Chart & Stats
HK$54.60
-HK$0.05(-0.24%)
At close: 4:00 PM EST
HK$54.60
-HK$0.05(-0.24%)
Day’s Range― - ―
52-Week RangeHK$27.00 - HK$71.25
Previous CloseN/A
Volume1.35K
Average Volume (3M)127.28K
Market Cap
HK$1.81B
Enterprise ValueHK$993.82M
Total Cash (Recent Filing)HK$718.20M
Total Debt (Recent Filing)HK$45.91M
Price to Earnings (P/E)21.9
Beta1.44
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.12
Shares Outstanding31,565,804
10 Day Avg. Volume119,990
30 Day Avg. Volume127,280
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.61
Price to Sales (P/S)4.47
P/FCF Ratio13.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.74
Revenue Forecast (FY)HK$541.30M
Bulls Say, Bears Say
Bulls Say
Profitability TurnaroundIn 2025 the company shifted to sustained profitability with materially higher gross and net margins. This reflects improved product mix and operating leverage as revenues scaled, creating a structural improvement in earnings quality that can support reinvestment and shareholder returns if maintained.
Improved Cash GenerationThe move to positive operating and free cash flow signals better cash conversion and self-funding capacity. Durable cash generation reduces reliance on external financing, supports capex and commercial expansion, and provides a buffer against cyclical dips if the cash profile remains stable.
Conservative Balance SheetVery low leverage and a sizable equity base provide financial flexibility and a capital buffer to absorb shocks. This conservatively financed balance sheet lowers refinancing risk and gives management scope to invest in growth or weather operational variability without immediate liquidity strain.
Bears Say
Earnings And Cash VolatilityRecent profitability follows multiple years of losses and wide swings in margins and cash flow. Such historical volatility implies execution and demand risk: a single adverse cycle or failed product rollout could quickly reverse profits and cash, undermining long-term stability.
Turnaround Durability RiskThe 2025 inflection may be structural but remains unproven across cycles. Sustaining margin expansion depends on continued revenue growth and cost discipline; any slowdown or competitive pressure could revert metrics, making the turnaround sensitive to execution and market conditions.
Reinvestment May Pressure ReturnsAlthough equity is sizeable today, prior losses reduced retained earnings and the company may need further investment to sustain growth. Significant capex or commercialization spend could dilute near-term ROE and cash generation unless operating margins and free cash flow stay consistently positive.
Shanghai Heartcare Medical Technology Corp. Ltd. Class H News
6609 FAQ
What was Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price range in the past 12 months?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H lowest stock price was HK$27.00 and its highest was HK$71.25 in the past 12 months.
What is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s market cap?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s market cap is HK$1.81B.
When is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s upcoming earnings report date?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s upcoming earnings report date is Aug 28, 2026 which is in 97 days.
How were Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s earnings last quarter?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H released its earnings results on Mar 26, 2026. The company reported HK$0.941 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.941.
Is Shanghai Heartcare Medical Technology Corp. Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price is currently Overvalued.
Does Shanghai Heartcare Medical Technology Corp. Ltd. Class H pay dividends?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H does not currently pay dividends.
What is Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s EPS estimate?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Heartcare Medical Technology Corp. Ltd. Class H have?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H has 31,565,804 shares outstanding.
What happened to Shanghai Heartcare Medical Technology Corp. Ltd. Class H’s price movement after its last earnings report?
Shanghai Heartcare Medical Technology Corp. Ltd. Class H reported an EPS of HK$0.941 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.091%.
Which hedge fund is a major shareholder of Shanghai Heartcare Medical Technology Corp. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6609
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
179.09%
12-Months-Change
Fundamentals
Return on Equity
7.53%
Trailing 12-Months
Asset Growth
12.12%
Trailing 12-Months
Company Description
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
Shanghai HeartCare Medical Technology Corporation Limited engages in the research, development, manufacture, and sale of neuro-interventional medical devices worldwide. The company offers ischemic stroke thrombectomy, intracranial stenosis treatment, ischemic stroke prevention, hemorrhagic stroke treatment, and vascular access devices. Its products are used for the treatment and prevention of ischemic stroke, including acute ischemic stroke and intracranial stenosis, as well as for the treatment of hemorrhagic stroke. The company was formerly known as Shanghai Care Medical Technology Corporation Limited. Shanghai HeartCare Medical Technology Corporation Limited was incorporated in 2016 and is headquartered in Shanghai, the People's Republic of China.
Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) Earnings & Revenues
Technical Analysis
Peijia Medical Ltd.
―
LifeTech Scientific Corporation
―
MicroPort CardioFlow Medtech Corp.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Venus Medtech (Hangzhou), Inc. Class H
―
Options Prices
Currently, No data available
---